We are an R&D services company founded by Dr. Kenneth Waterman. The company develops innovative technologies for a range of applications from pharmaceuticals to military needs. The company maintains laboratory facilities in Groton, CT which house corporate R&D operations and supports accelerated stability studies on behalf of clients. FreeThink Technologies is best known for ASAPprime®, a software-based tool that allows pharmaceutical companies to determine drug substance and drug product stability more rapidly and more accurately than previously possible.
FreeThink Technologies, Inc. is a private R&D company founded by Dr. Kenneth Waterman in 2011. The company develops innovative technologies for a range of applications from pharmaceuticals to military needs. The company’s laboratories are located in Groton, Connecticut, where its experimental research is conducted.
In addition to helping develop new inventions, providing data to support current products and advancing science, our laboratories also provide clients with hands-on support for stability studies.
Where appropriate, FreeThink Technologies partners with other companies to advance and commercialize its ideas. While FreeThink Technologies will seek opportunities to patent its technologies, it is also committed to publishing scientific papers and presenting work at conferences and universities.
FreeThink Technologies first commercial product is ASAPprime® software, a package that allows pharmaceutical companies to determine drug substance and drug product stability more rapidly and more accurately than previously possible.
We provide tools and services which enable our customers to rapidly and accurately determine drug substance and drug product stability. We also leverage these technologies in other sectors such as electronics, protective coatings and food industries to speed development while assuring adequate storage stability.
Our expertise in drug delivery technologies include oral controlled release, chewable tablets and powders for oral suspension. We use this expertise to develop innovative drug delivery platforms and to help solve drug delivery challenges.
Prodrugs are inactive forms of drugs that convert to the active drug only when ingested by the patient, enabling improved drug absorption and greater tolerability. We are using our expertise to identify, synthesize and test prodrugs to provide medical advantages for marketed drugs.